Prostate Cell News 8.31 August 18, 2017 | |
| |
TOP STORYDiscovery of New Prostate Cancer Biomarkers Could Improve Precision Therapy Researchers have identified a new cause of treatment resistance in prostate cancer. They explained the role of mutations within the SPOP gene on the development of resistance to one class of drugs. SPOP mutations were the most frequent genetic changes seen in primary prostate cancer. These mutations played a central role in the development of resistance to drugs called BET-inhibitors. [Press release from the Mayo Clinic discussing online prepublication in Nature Medicine] Press Release | Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)LABORATORY RESEARCHScientists showed the tumor-suppressor role of SPOP in prostate cancer in which it acted as a negative regulator of bromodomain and extraterminal (BET) protein stability and also provided a molecular mechanism for resistance to BET inhibitors in individuals with prostate cancer bearing SPOP mutations. [Nat Med] Abstract The authors report that the splicing of androgen receptor (AR) variants AR-V7 as well as AR-V1 and AR-V9 was regulated coordinately by a single polyadenylation signal in AR intron 3. Blocking this signal with morpholino technology or silencing of the polyadenylation factor CPSF1 caused a splice switch that inhibited expression of AR variants and blocked androgen-independent growth of castration resistant prostate cancer. [Cancer Res] Abstract Researchers identified the type 1, 2, and 4 collagen–binding protein transforming growth factor–β–induced protein (TGFBI) as an important factor in the epithelial-to-mesenchymal transition and malignant progression of prostate cancer. In prostate cancer cell lines, androgen receptor (AR) signaling stimulated the activity of the transcription factor SPDEF, which repressed the expression of TGFBI. Androgen deprivation therapy, AR antagonism, or overexpression of TGFBI inhibited the activity of SPDEF and enhanced the proliferation rates of prostate cancer cells. [Sci Signal] Full Article Scientists showed the possibility of using genetic engineering techniques to program various functionalities into one single chain vector and create a multifunctional non-immunogenic biomacromolecule for targeted gene transfer to prostate cancer cells. [Biomacromolecules] Abstract Myosin Isoform Expressed in Metastatic Prostate Cancer Stimulates Cell Invasion Metastatic prostate cancer is differentiated by expression of the rare isoform A of the molecular motor myosin IC, however the function of this isoform remained unknown. Investigators showed that it contributes causatively to the invasive motility of prostate cancer cells. They found that the isoform associates with metalloprotease-containing exosomes and stimulates their secretion. [Sci Rep] Full Article Bone-Targeted Cabazitaxel Nanoparticles for Metastatic Prostate Cancer Skeletal Lesions and Pain Researchers developed nanoparticles using poly(D,L-lactic-co-glycolic acid) and cabazitaxel as the core with amino-bisphosphonate surface conjugation. Optimization of nanoparticle physiochemical properties, in vitro evaluation in prostate cancer cell lines and in vivo testing in an intraosseous model of metastatic prostate cancer was performed. [Nanomedicine (Lond)] Full Article Targeting AR Variant-Coactivator Interactions to Exploit Prostate Cancer Vulnerabilities Active androgen receptor splice variants (AR-Vs) represent a well-established mechanism of therapeutic resistance and disease progression. Signaling by AR-Vs, including the clinically relevant AR-V7, is augmented by Vav3, an established AR coactivator in castration-resistant prostate cancer. Using mutational and biochemical studies, scientists demonstrated that the Vav3 Diffuse B-cell lymphoma homology domain interacted with the N-terminal region of AR-V7. [Mol Cancer Res] Abstract CLINICAL RESEARCH | |
| |
REVIEWSThe authors discuss the critical role of B cell lymphoma gene number 2 (BCL-2) in the carcinogenesis of prostate cancer with experimental evidences on the BCL-2 molecular networks in androgen-independent prostate cance (AIPC) and androgen-dependent prostate cancer and subsequently suggest perspective research targeting BCL-2. [Expert Opin Ther Targets] Abstract Visit our reviews page to see a complete list of reviews in the prostate cell research field. | |
| |
INDUSTRY NEWSVituro Health Expands into Arkansas, Providing the Latest in Precision Prostate Cancer Care Vituro Health and Arkansas Urology partnered to offer patients in Arkansas and surrounding states the latest, most innovative technologies in prostate cancer treatment and precision disease management. [Vituro Health] Press Release Stanford and Takeda Pharmaceuticals to Collaborate on Medicines of the Future A new partnership between Stanford and Takeda Pharmaceutical Company Ltd., could help speed up the process of bringing drugs from discovery to market. [Stanford University] Press Release | |
| |
POLICY NEWSNSF Reiterates Policy on Teaching Good Research Habits despite Its Limitations The National Science Foundation (NSF) in Arlington, Virginia, has decided to double down on its implementation of a congressionally mandated policy aimed at reducing research misconduct among NSF-funded scientists, despite a new report that notes problems with the agency’s approach. [ScienceInsider] Editorial China’s Embrace of Embryo Selection Raises Thorny Questions Fertility centers are making a massive push to increase preimplantation genetic diagnosis in a bid to eradicate certain diseases. [Nature News] Editorial Budget Cuts Fuel Frustration among Japan’s Academics Japan’s premier scientific research institution, RIKEN, turned 100 this year, and celebrated with a grand ceremony attended by the empress and emperor. But not everybody was in the mood to party. In the old days, RIKEN was known as a paradise for scientists because of its generous funding. No longer: as Japan cuts off funds in the face of continuing financial uncertainty, the cracks are starting to show. [Nature News] Editorial New FDA Security Rules Will Bar Agency from Hiring Some Foreign Nationals The FDA is moving to adopt a new policy on security background checks that is sowing confusion and alarm among some of its scientists. The change, described in a “communications plan” shared with the agency’s senior staff in recent weeks, appears to effectively bar the agency from hiring—as employees or contractors—foreign nationals who have not lived in the United States for a total of three out of the last five years. [ScienceInsider] Editorial
| |
EVENTSNEW EACR-MRS: Seed and Soil: In Vivo Models of Metastasis Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Position – Prostate Cancer (Moffitt Cancer Center) Postdoctoral Research Fellow – Prostate Cancer (Edith Cowan University) Postdoctoral Fellowship – Translational Cancer Disparities Research (Duke Cancer Institute) Postdoctoral Research Associate – Prostate Cancer (University of South Carolina) Postdoctoral Position – Prostate Cancer (Baylor College of Medicine) Postdoctoral Scholar Position – Prostate Cancer (Case Western Reserve University) Postdoctoral Position – Prostate Cancer (Cleveland Clinic) Postdoctoral Position – Prostate Related Diseases (Baylor College of Medicine) Assistant Member – Prostate Cancer (Fred Hutchinson Cancer Research Center) Postdoctoral Fellow – Drug Discovery (The Vancouver Prostate Centre) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Prostate Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|